Rand study suggests hospitals are exorbitantly overpaid by private insurers; AHA reacts

If private insurers and employers paid hospitals at Medicare rates, their collective bill in 2018 would have been almost 60% lower than what they paid.

In real dollars, these payers’ combined savings would have nearly reached $20 billion.

That’s according to a new analysis from the Rand Corporation, which reviewed data from 3,112 community hospitals across all states except Maryland.

Looking at $34 billion worth of claims filed for around 750,000 inpatient stays and 40 million outpatient visits, lead researcher Christopher Whaley and colleagues found wide variations by state and, overall, an average above-Medicare tab of 247%.

In a press release, Whaley comments that some of the highest prices may have been warranted by exceptional quality or highly specialized care.

“However, if two hospitals have similar quality, then any difference in prices may be harder to justify,” Whaley says.

Especially during the COVID-19 pandemic, he adds, “employers need transparent information on the prices that they and their employees are paying for healthcare services.”

Katherine Hempstead of the Robert Wood Johnson Foundation, which sponsored the study, says the gap in private vs. public hospital prices raises questions about efficiency in the former.

“The goal of this work is to arm employers with data so they can negotiate more effectively,” Hempstead says. “Curbing excessive spending on employer health insurance is in the public interest.”

The report’s supplemental materials include relative and standardized prices for each analyzed facility, along with CMS Hospital Compare star ratings.

Meanwhile the American Hospital Association has issued a pointed response to the Rand study.

Tom Nickels, the AHA’s executive vice president, says the Rand report erroneously suggests private payers would do well to benchmark Medicare rates despite their understanding that CMS reimburses well below the cost of providing care.

Nickels also upbraids the Rand team for taking research shortcuts and “cherry picking” data to analyze.

“These concerns are compounded by a global pandemic that represents the greatest financial threat in history for hospitals and health systems,” Nickels says. “The case for pulling resources from care providers was weak from the start. It is beyond reckless to advance this approach now.”

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.